Get Live Data

The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here. 

Less Ads, More Data, More Tools Register for FREE
GreenRoc Accelerates their World Class Project to Production as Early as 2028
GreenRoc Accelerates their World Class Project to Production as Early as 2028View Video

Latest Share Chat

  2. Share Prices
  3. Hutchmed Share Price
  4. Hutchmed Share News
  5. UK earnings, trading statements calendar - next 7 days

Pin to quick picksHutchmed Share News (HCM)

Hutchmed Information

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 290.00
Bid: 286.00
Ask: 291.00
Change: -1.00 (-0.34%)
Spread: 5.00 (1.748%)
Open: 290.00
High: 291.00
Low: 290.00
Prev. Close: 291.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK earnings, trading statements calendar - next 7 days

Thu, 24th Feb 2022 15:54

Friday 25 February 
Evraz PLCFull Year Results
IMI PLCFull Year Results
International Consolidated Airlines Group SAFull Year Results
Jupiter Fund Management PLCFull Year Results
Pearson PLCFull Year Results
Rightmove PLCFull Year Results
Monday 28 February 
Associated British Foods PLCTrading Statement
BATM Advanced Communications LtdFull Year Results
Bunzl PLCFull Year Results
CentralNic Group PLCFull Year Results
GlobalData PLCFull Year Results
Greencoat Renewables PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Kitwave Group PLCFull Year Results
Kosmos Energy LtdQ4 Results
Made Tech Group PLCHalf Year Results
RHI Magnesita NVFull Year Results
Tuesday 1 March 
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Flutter Entertainment PLCFull Year Results
Hotel Chocolat Group PLCHalf Year Results
Intertek Group PLCFull Year Results
Man Group PLCFull Year Results
PCI-PAL PLCHalf Year Results
Quartix Technologies PLCFull Year Results
Reach PLCFull Year Results
Revolution Bars Group PLCHalf Year Results
Rotork PLCFull Year Results
Travis Perkins PLCFull Year Results
Uniphar PLCFull Year Results
Vitec Group PLCFull Year Results
XP Power LtdFull Year Results
Wednesday 2 March 
Polymetal International PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Vistry Group PLCFull Year Results
Nichols PLCFull Year Results
Hotel Chocolat Group PLCHalf Year Results
Devro PLCFull Year Results
KRM22 PLCFull Year Results
Supermarket Income REIT PLCHalf Year Results
Foxtons Group PLCFull Year Results
Persimmon PLCFull Year Results
Hiscox PLCFull Year Results
musicMagpie PLCFull Year Results
Vivo Energy PLCFull Year Results
Aviva PLCFull Year Results
Thursday 3 March 
Admiral Group PLCFull Year Results
Avation PLCHalf Year Results
Coats Group PLCFull Year Results
CRH PLCFull Year Results
Darktrace PLCHalf Year Results
Dotdigital GroupFull Year Results
Elementis PLCFull Year Results
Empiric Student Property PLCFull Year Results
Entain PLCFull Year Results
Franchise Brands PLCFull Year Results
Galliford Try Holdings PLCHalf Year Results
Hansard Global PLCHalf Year Results
Hutchmed (China) LtdFull Year Results
ITV PLCFull Year Results
London Stock Exchange Group PLCFull Year Results
Meggitt PLCFull Year Results
Melrose Industries PLCFull Year Results
Mondi PLCFull Year Results
PageGroup PLCFull Year Results
Rentokil Initial PLCFull Year Results
Schroders PLCFull Year Results
Spire Healthcare Group PLCFull Year Results
Synthomer PLCFull Year Results
Taylor Wimpey PLCFull Year Results
Tritax Big Box REIT PLCFull Year Results
Tyman PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
7 Feb 2024 09:50

Hutchmed hails fruquintinib trial results for gastric cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in overall survival for patients with gastric or gastroesophageal junction adenocarcinoma.

Read more
2 Feb 2024 09:52

Hutchmed says Inmagene exercises option to licence drug candidates

(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of a strategic partnership.

Read more
2 Feb 2024 09:42

Hutchmed partner Inmagene exercises options over two drug candidates

(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.

Read more
30 Jan 2024 10:32

Hutchmed's 'Elunate' approved under new Hong Kong rules

(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).

Read more
30 Jan 2024 09:20

Hutchmed celebrates cancer drug approval in hometown of Hong Kong

(Alliance News) - Hutchmed (China) Ltd on Tuesday touted progress in Hong Kong, after its oral therapy for metastatic colorectal cancer received marketing approval in the city.

Read more
11 Jan 2024 11:11

Hutchmed application for thrombocytopenia treatment accepted in China

(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), had been accepted for review and granted priority review by China's National Medical Products Administration (NMPA).

Read more
11 Jan 2024 10:17

TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau

(Alliance News) - Hutchmed Ltd on Thursday said that its novel treatment for haematological malignancies and immune diseases had been progressed to the next stage of approval by the country's national bureau for drug supervision.

Read more
21 Dec 2023 11:36

IN BRIEF: Hutchmed China renews deals with "substantial" shareholders

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Agrees with "substantial shareholder" Sinopharm Group Co Ltd to renew the Framework Sinopharm Products Supply & Purchase Agreement, effective from January 1, for three years up to and including December 31, 2026. Also agrees with HCMH to renew the HBYS Brand License Royalty agreement, also effective from January 1 and for the same duration. HCMH entered the HBYS deal in June 2021 with HWEL, a subsidiary of major shareholder CK Hutchison Holdings Ltd which holds an approximate 38.18% stake in Hutchmed.

Read more
13 Dec 2023 13:56

Hutchmed completes enrolment for fruquintinib trial

(Alliance News) - Hutchmed (China) Ltd on Wednesday said it has completed enrolment of its phase II/III trial of fruquintinib.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
9 Nov 2023 12:16

Hutchmed hails Takeda's fruquintinib approval from US for cancer form

(Alliance News) - Hutchmed (China) Ltd on Thursday announced that the Tokyo-based drug maker, Takeda Pharmaceutical Co Ltd, has received US approval of fruquintinib for a form of colorectal cancer.

Read more
29 Sep 2023 10:57

Hutchmed confirms new drug application for fruquintinib in Japan

(Sharecast News) - Hutchmed China announced on Friday that its partner Takeda has officially submitted a new drug application (NDA) for fruquintinib to the Ministry of Health, Labour and Welfare (MHLW) in Japan.

Read more
29 Sep 2023 10:12

Hutchmed notes Takeda submits fruquintinib drug application in Japan

(Alliance News) - Hutchmed (China) Ltd on Friday said Takeda Pharmaceutical Co Ltd has submitted a new drug application for cancer treatment fruquintinib to the Ministry of Health, Labour & Welfare in Japan.

Read more
14 Sep 2023 13:09

Director dealings: IPF non-exec picks up shares, Hutchmed China director linked to sale

(Sharecast News) - International Personal Finance was among the companies on the list of director purchases on Thursday after a non-executive director spent more than £18k on shares.

Read more
12345678910

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.